RxDoctor Payments Data

Eric Chatman, MD

Internal Medicine · Opelousas, LANPI 1366520298

Payments from drug & device makers

$2,745in general payments, 2019–2025

Across 138 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$966
  • Novo Nordisk$523
  • Novartis$288
  • Pfizer$287
  • Lilly USA, LLC$166
  • Boehringer Ingelheim$163
  • plus $351 from 5 others

What the payments were for

  • Food & beverage$2,739100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,745 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$77,354
Medicare patients
75
Services billed
1,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$71,480
JardianceEmpagliflozin63$61,332
FarxigaDapagliflozin Propanediol74$52,905
RybelsusSemaglutide22$46,108
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$46,096
TrulicityDulaglutide33$34,369
Xigduo XrDapaglifloz Propaned/Metformin36$30,818
Synjardy XrEmpagliflozin/Metformin Hcl40$29,702
LinzessLinaclotide29$21,770
MounjaroTirzepatide16$20,425
Janumet XrSitagliptin Phos/Metformin Hcl23$12,078
EliquisApixaban15$11,778
KerendiaFinerenone14$11,461
Rosuvastatin Calcium562$7,271
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$523$117,58777 claims
Boehringer IngelheimJardiance, Synjardy Xr$163$91,034103 claims
AstraZenecaFarxiga, Breztri Aerosphere$966$59,71685 claims
Lilly USA, LLCTrulicity, Mounjaro$166$54,79449 claims
GSKTrelegy Ellipta$160$46,09663 claims
PfizerEliquis$287$11,77815 claims
BayerKerendia$85$11,46114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Opelousas

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →